Clinical Trials Logo

Predictive Biomarkers clinical trials

View clinical trials related to Predictive Biomarkers.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06097936 Recruiting - Clinical trials for PREDICTIVE BIOMARKERS

New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer

Start date: March 15, 2021
Phase:
Study type: Observational

The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.

NCT ID: NCT05813418 Recruiting - Immunotherapy Clinical Trials

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Ibe2i-TIPCI
Start date: July 2, 2021
Phase: N/A
Study type: Interventional

In the last decades, cancer treatment was based on surgery, radiotherapy and chemotherapy. Recently, treatments have largely evolved, first with targeted therapies (notably tyrosin kinase inhibitors, TKI) and then with immune checkpoint inhibitors (ICPI, notably anti-CTLA-4 and anti- PD1). The last ones can induce durable anti-tumoral responses in patients, even if metastases are present. Their mechanisms of action are focused on the activation of immune system in order to eliminate the tumor. ICPI, because of their mechanisms of action, target immune tolerance key components and can induce important immune toxicities (colitis, hepatitis, dermatitis, thyroiditis ...), leading to early discontinuation of treatment, severe or chronic morbidity, and can sometimes be lethal. It is of importance to detect patient at risk of irAEs, because of the increasing use of ICPI and the long- term response capacity in treated patients.

NCT ID: NCT04227886 Recruiting - Adenocarcinoma Clinical Trials

Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer

Start date: December 1, 2019
Phase:
Study type: Observational

Backgrounds: A multicenter randomized phase III trial (NCT02605265) proved that adding irinotecan guided by UGT1A1 to capecitabine-based neoadjuvant chemoradiotherapy significantly increases complete tumor response. The treatment toxicities were increased but tolerable. Purposes: This study aims to identify the predictive biomarkers (from patients' tumor biopsy samples and peripheral blood samples before neoadjuvant therapy) for predicting the response and toxicities to neoadjuvant therapy to stratify patients and optimize treatment strategy.